English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech BioTech (Sci&Research)
以岭药业向上合组织捐赠296万元连花清瘟支持疫情防控
Aug 06, 2020 17:58 HKT
以嶺藥業向上合組織捐贈296萬元連花清瘟支持疫情防控
Aug 06, 2020 17:59 HKT
Novotech榮膺全球職場文化權威機構認證的“2020 年最佳職場”稱號
Aug 05, 2020 09:00 HKT
Novotech荣膺全球职场文化权威机构认证的“2020 年最佳职场”称号
Aug 05, 2020 09:00 HKT
전략적 기회: ‘호주에서 수행하는 인간대상 첫 임상시험 및 백신 임상시험’ – 노보텍 (Novotech) 웨비나
Aug 03, 2020 12:00 HKT
노보텍 (Novotech), 세계적 권위의 직장문화 기관으로부터 ‘2020년의 좋은 직장’ 인증 받아
Aug 03, 2020 11:00 HKT
Captiva Verde Announces Esmeralda Agreement with Mexican Health Care Workers Union for up to USD$142 Million per Year of Annual Product Sales
Jul 28, 2020 07:00 HKT
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
Jul 31, 2020 15:00 HKT
Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM
Jul 27, 2020 15:18 HKT
MP Biomedicals and A*STAR Co-Develop Rapid Antibody Test Kit for SARS-CoV-2
Jul 24, 2020 17:00 HKT
아방스 클리니컬, 아토사 테라퓨틱스의 두 번째 코로나19 치료제 개발 프로그램인 비강 분무용 치료제 AT-301 임상 연구 계약
Jul 23, 2020 06:00 HKT
Avance Clinical簽約展開Atossa Therapeutics AT-301鼻噴霧劑臨床研究,這是Atossa的第二個新冠肺炎治療開發項目
Jul 23, 2020 06:00 HKT
Avance Clinical签约展开Atossa Therapeutics AT-301鼻喷雾剂临床研究,这是Atossa的第二个新冠肺炎治疗开发项目
Jul 23, 2020 06:00 HKT
中国抗体与D2M建立战略合作关系
Jul 23, 2020 07:22 HKT
中國抗體與D2M建立戰略合作關係
Jul 23, 2020 07:21 HKT
SinoMab entered into Strategic Collaboration with D2M
Jul 23, 2020 07:20 HKT
君实生物抗Trop2单抗-Tub196偶联剂JS108获准进入临床试验
Jul 22, 2020 08:41 HKT
嘉和生物药业宣布新药Geptanolimab上市申请已获受理 并任命陈文德先生为首席运营官
Jul 21, 2020 17:40 HKT
嘉和生物藥業宣佈新藥Geptanolimab上市申請已獲受理 並任命陳文德先生為首席運營官
Jul 21, 2020 17:38 HKT
Genor Biopharma Announces Acceptance of New Drug Application for Geptanolimab and Appointment of Mr. CHEN Wende as Chief Operation Officer
Jul 21, 2020 17:37 HKT
Next >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: